|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||
  Journal of Cardiovascular ElectrophysiologyVolume 19 Issue 4, Pages 362 - 366 Published Online: 13 Feb 2008 Journal compilation © 2010 Wiley Periodicals, Inc.
Abstract | References | Full Text: HTML, PDF (Size: 72K) | Related Articles | Citation Tracking  Periprocedural Anticoagulation for Atrial Fibrillation Ablation Manuscript received 8 August 2007; Revised manuscript received 3 October 2007; Accepted for publication 26 October 2007. Copyright ©Journal compilation 2008 Blackwell Publishing KEYWORDS
atrial fibrillation
•
ablation
•
stroke
•
warfarin
•
aspirin
AF and Anticoagulation. (J Cardiovasc Electrophysiol, Vol. 19, pp. 362–366, April 2008) ABSTRACTBackground: Catheter ablation for atrial fibrillation (AF) can increase risk of left atrial (LA) thrombi and stroke. Optimal periprocedural anticoagulation has not been determined. Objective: We report the role of administering warfarin and aspirin without low molecular weight heparin in patients undergoing AF ablation. Methods: A total of 207 patients underwent ablation for AF. Transesophageal echocardiography (TEE) guided transseptal puncture and ruled out clot in the LA. After first puncture, the sheath was flushed with heparin (5,000 Units/mL). After second puncture, a bolus of 80 units/kg of heparin was given, followed by an infusion to maintain activated clotting time (ACT) around 300–350 seconds. Warfarin was stopped and aspirin was started (325 mg/day) 3 days preprocedure. Warfarin was restarted on the day of the procedure. Both medications were continued for 6 weeks postablation. Warfarin was continued for 6 months in patients with prior history of persistent or recurrent AF. Thirty-seven patients who showed smoke in the LA on TEE were given low molecular weight heparin postprocedure until international normalized ratio (INR) was therapeutic. Results: Thirty-two patients had persistent and 175 had paroxysmal AF; 87 were cardioverted during ablation. Two patients had transient ischemic attack (TIA) on the sixth and eighth days, respectively, following ablation, with complete recovery. Both had subtherapeutic INRs. Conclusion: In patients without demonstrable clot or smoke in the LA, starting aspirin 3 days prior and warfarin immediately post-radiofrequency ablation, without low molecular weight heparin, with meticulous anticoagulation during the procedure, appears to be a safe mode of anticoagulation. Received: 08 August 2007; First Revision: 03 October 2007; Accepted: 26 October 2007; | 
|
